CA-ADVA
24.1.2023 18:01:38 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Brandywine Communications is using its OSA 5422 grandmaster clock to deliver a robust and feature-rich M-Code timing solution for use cases such as US Department of Defense applications. The new edge synchronization offering addresses the key requirements of military networks by providing enhanced positioning, navigation and timing (PNT) capabilities and improved resilience. Built on Oscilloquartz’s versatile timing technology with integrated M-Code capabilities, the solution is ideal for the most demanding military edge applications. It supports 1Gbit/s and 10Gbit/s interfaces, provides innovative GNSS assurance capabilities as well as backup through Oscilloquartz’s assured PNT (aPNT+™) technology, and meets the most stringent timing demands in an operationally efficient and cost-effective way.
“Our M-Code edge timing offering will be a game-changer for defense applications. Powered by ADVA’s OSA 5422 grandmaster clock, it meets the most urgent needs of military networks that require precise and reliable PNT information and delivers new levels of reliability and security. One key feature of the OSA 5422 is its long holdover and PTP backup, which enables it to maintain accurate timing even in the event of M-Code disruption. This is critical for pressurized defense networks that need to operate in a variety of difficult environments,” said Allen Ronk, president of Brandywine Communications. “Our solution features multi-source backup capabilities to ensure that M-Code outages do not disrupt synchronization. It also provides sync assurance capabilities that continually monitor the performance of the timing system and take immediate corrective action when needed.”
M-Code is an encrypted GPS signal used exclusively by the US military in defense applications that require precise and reliable synchronization. Resistant to jamming and spoofing, M-Code is an invaluable asset for defense organizations operating in challenging conditions. ADVA’s OSA 5422 grandmaster clock is now integrated with a highly reliable M-Code receiver that meets stringent frequency and phase synchronization needs and offers the best holdover performance of any edge device on the market. Also equipped with multi-band, multi-constellation GNSS receivers for when M-Code is not available, the device offers support for legacy interfaces such as BITS and IRIG, and features eight field-upgradeable 10Gbit/s ports and 1Gbit/s interfaces. The OSA 5422 is also environmentally hardened with hot-swappable modules and power supplies for easy field upgrades.
“As military applications demand increasingly precise and reliable PNT capabilities, the need for secure, jamming- and spoofing-resistant M-Code technology becomes ever more pressing. With its long holdover, multi-source backup capabilities, sync assurance capabilities, and other advanced features, our OSA 5422 is perfectly positioned to meet this demand,” commented Gil Biran, GM of Oscilloquartz, ADVA. “We’re excited to be working with Brandywine Communications as our strategic partner and to be bringing our innovation to defense applications that rely on precise and reliable PNT in the US and elsewhere. The market for military GPS receivers with M-Code capabilities is growing, as defense organizations seek to enhance their PNT capabilities and improve resilience. Together, we’re helping empower a whole new section of customers to benefit from the industry’s most agile synchronization toolkit.”
ADVA’s Oscilloquartz aPNT+™ and M-Code technology is being showcased at the Precise Time and Time Interval Systems and Applications Meeting (PTTI 2023) in Long Beach, California, from January 23 to 26. Attendees can visit the Oscilloquartz team at Brandywine Communications’ booth to learn about the platform’s ability to provide resilient and assured PNT services for military applications in line with the Department of Defense’s latest zero-trust strategy, and how the OSA 5422 supports both time-as-a-service (TaaS) and GNSS-backup-as-a-service (GBaaS).
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005723/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom